Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. More Details
Adequate balance sheet with proven track record.
Share Price & News
How has Supernus Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SUPN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: SUPN's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: SUPN underperformed the US Pharmaceuticals industry which returned 7.4% over the past year.
Return vs Market: SUPN underperformed the US Market which returned 22.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Supernus Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StSupernus Pharmaceuticals (NASDAQ:SUPN) Shareholders Booked A 48% Gain In The Last Five Years
3 weeks ago | Simply Wall StCalculating The Fair Value Of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
3 months ago | Simply Wall StInvestors Aren't Buying Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Earnings
Is Supernus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SUPN ($21.67) is trading above our estimate of fair value ($11.57)
Significantly Below Fair Value: SUPN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SUPN is good value based on its PE Ratio (8.8x) compared to the US Pharmaceuticals industry average (21.8x).
PE vs Market: SUPN is good value based on its PE Ratio (8.8x) compared to the US market (19.4x).
Price to Earnings Growth Ratio
PEG Ratio: SUPN's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: SUPN is good value based on its PB Ratio (1.6x) compared to the US Pharmaceuticals industry average (3.6x).
How is Supernus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SUPN's earnings are forecast to decline over the next 3 years (-24.8% per year).
Earnings vs Market: SUPN's earnings are forecast to decline over the next 3 years (-24.8% per year).
High Growth Earnings: SUPN's earnings are forecast to decline over the next 3 years.
Revenue vs Market: SUPN's revenue is expected to decline over the next 3 years (-0.5% per year).
High Growth Revenue: SUPN's revenue is forecast to decline over the next 3 years (-0.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SUPN's Return on Equity is forecast to be high in 3 years time
How has Supernus Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SUPN has high quality earnings.
Growing Profit Margin: SUPN's current net profit margins (27.1%) are higher than last year (26%).
Past Earnings Growth Analysis
Earnings Trend: SUPN's earnings have grown significantly by 24.6% per year over the past 5 years.
Accelerating Growth: SUPN's earnings growth over the past year (22.1%) is below its 5-year average (24.6% per year).
Earnings vs Industry: SUPN earnings growth over the past year (22.1%) exceeded the Pharmaceuticals industry 16.8%.
Return on Equity
High ROE: SUPN's Return on Equity (18.2%) is considered low.
How is Supernus Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: SUPN's short term assets ($552.0M) exceed its short term liabilities ($299.6M).
Long Term Liabilities: SUPN's short term assets ($552.0M) exceed its long term liabilities ($501.5M).
Debt to Equity History and Analysis
Debt Level: SUPN's debt to equity ratio (50.4%) is considered high.
Reducing Debt: SUPN's debt to equity ratio has increased from 7.4% to 50.4% over the past 5 years.
Debt Coverage: SUPN's debt is well covered by operating cash flow (42%).
Interest Coverage: SUPN's interest payments on its debt are well covered by EBIT (40.5x coverage).
What is Supernus Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SUPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SUPN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SUPN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SUPN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SUPN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jack Khattar (59 yo)
Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has been its Chief Executive Officer, President, Secretary and Director since 2005. From 1999 to ...
CEO Compensation Analysis
Compensation vs Market: Jack's total compensation ($USD8.12M) is above average for companies of similar size in the US market ($USD2.60M).
Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.
|Chief Scientific Officer & Senior VP of Intellectual Property||8.75yrs||US$1.31m||0% |
|Senior Vice President of Regulatory Affairs||no data||US$874.82k||0.16% |
|Chief Medical Officer and Executive VP of Research & Development||8.42yrs||US$1.47m||0.0053% |
|Executive VP & CFO||0.17yr||no data||no data|
|Vice President of Marketing||5.92yrs||no data||no data|
|Vice President of Sales||5.92yrs||no data||no data|
|Vice President of Corporate Development||5.42yrs||no data||no data|
|Senior Vice President of Quality||0.92yr||no data||0.012% |
|Senior Vice-President of Clinical Research & Medical Affairs||0.83yr||no data||no data|
Experienced Management: SUPN's management team is seasoned and experienced (5.9 years average tenure).
|Independent Chairman of the Board||4.33yrs||US$375.95k||0.18% |
|Independent Director||9.92yrs||US$357.45k||0.11% |
|Independent Director||5.75yrs||US$342.45k||0% |
|Independent Director||2.5yrs||US$324.95k||0% |
|Independent Director||10.92yrs||US$359.95k||0.024% |
Experienced Board: SUPN's board of directors are considered experienced (7.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Supernus Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Supernus Pharmaceuticals, Inc.
- Ticker: SUPN
- Exchange: NasdaqGM
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.158b
- Shares outstanding: 52.69m
- Website: https://www.supernus.com
Number of Employees
- Supernus Pharmaceuticals, Inc.
- 9715 Key West Avenue
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SUPN||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||May 2012|
|S49||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2012|
|0LB2||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 2012|
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in th...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/02 23:09|
|End of Day Share Price||2020/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.